

# Does Prior Training Affect Acute O<sub>2</sub> Supply Responses During Exercise in Desaturator COPD Patients?

Delphine Delamplé<sup>\*,1,2</sup>, Meritxell Sabate<sup>2</sup>, Christian Préfaut<sup>1</sup> and Fabienne Durand<sup>1,2</sup>

<sup>1</sup>INSERM ERI25 «Muscle and Pathologies», F-34295 Montpellier, France. Université Montpellier I, EA4202, F-34295 Montpellier, France

<sup>2</sup>Laboratoire SSA “Sport Santé Altitude”, Département STAPS, Font-Romeu, France

**Abstract:** *Background:* This study investigated the effects of a prior individualized training program (TP) on the response to acute oxygen supply during exercise in chronic obstructive pulmonary disease (COPD) patients showing exercise-induced desaturation.

*Methods:* Twenty-two COPD patients (mean [SD] FEV1 = 52.1 [3] % predicted) who desaturated on exercise participated in a TP. Exercise tolerance while breathing compressed air or oxygen was assessed using a walking test (WT) before and after TP. Oxygen flow was individualized.

*Results:* Before TP, acute oxygen supply improved mean exercise tolerance. But this response was heterogeneous as only 8 patients increased their walking distance with oxygen. TP improved exercise tolerance in the entire population. However, a greater effect of oxygen administration during exercise was not observed after TP. The response to oxygen again showed great disparity as only 6 patients increased their walking distance with oxygen after TP.

*Conclusion:* The response to oxygen supply during exercise varied among COPD patients. Moreover, despite the clinical benefits of TP, no cumulative effect of TP and oxygen supply was observed during exercise performance.

**Keywords:** COPD, training program, oxygen, exercise.

## INTRODUCTION

Exercise-induced desaturation is well reported in patients with chronic obstructive pulmonary disease (COPD) [1]. Indeed, some COPD patients do not exhibit clinical resting hypoxemia, i.e. an arterial oxygen pressure (PaO<sub>2</sub>) less than 55 mmHg, but they do show significant exercise-induced desaturation; these patients have been termed “desaturators” [2]. The six-minute walking test (WT) [1], a reliable clinical test to explore exercise tolerance in COPD patients, easily detects this desaturation. To correct this desaturation, oxygen is prescribed for desaturator patients to adjust the O<sub>2</sub> saturation (SpO<sub>2</sub>) above 90% during exercise and especially the exercise included in rehabilitation programs. Recently, Bradley *et al.* [3] reviewed the evidence from single-assessment studies that this ambulatory O<sub>2</sub> improves exercise performance in COPD patients but noted that the magnitude of improvement is unclear. The reports on the short-term O<sub>2</sub> benefits to these patients during exertion are indeed conflicting; some of the studies mentioned in Bradley’s review reported an increase in exercise performance [4-9], whereas others did not [10, 11]. Moreover, the values of the variables investigated to assess the responses to O<sub>2</sub> show great heterogeneity, which could lead to an average benefit that lacks significance. In fact, it may be that in some COPD patients O<sub>2</sub> is available to the exercising muscles (because SpO<sub>2</sub> is corrected) but is not used, suggesting that the peripheral muscles of these patients are unsuitable for O<sub>2</sub> use.

Differences in exercise testing protocols, the prescribed flow, and/or disease severity have probably contributed to these divergent results [3]. For example, all the studies that reported a benefit from O<sub>2</sub> used an O<sub>2</sub> flow that was not individualized in relation to the O<sub>2</sub> desaturation but was instead predetermined. As we know that the O<sub>2</sub> supply has a dose-response effect [9], this methodology seems not well adapted and may be far from rehabilitation reality. Moreover, in all the studies that examined the short-term benefits of O<sub>2</sub> in COPD, no data were given on the training status of the desaturator subjects. It has been suggested that the exercise-induced desaturation observed during a WT could be linked to muscle characteristics [1]. It is also well known that training can act on these muscle characteristics to improve muscle function [12], with not only increases in aerobic enzymes and the capillary density of leg muscles [13], but also a changed breathing pattern with higher tidal volume and lower breathing frequency [14, 15]. As a consequence, after TP, utilization of oxygen by COPD muscle should be more efficient and exercise performance increased.

This study thus tests the hypothesis that prior individualized training in desaturator COPD patients will increase acute O<sub>2</sub> supply effects on the exercise performance.

## MATERIAL AND METHODS

### Population

Twenty-two patients with mild to severe COPD as defined by the Global Initiative for Chronic Obstructive Lung Disease guidelines [16] were recruited from an inpatient clinic before TP. All were desaturators as they presented significant O<sub>2</sub> desaturation during WT, i.e. a fall in SpO<sub>2</sub> of at least 4% over 3 minutes [1]. In addition, SpO<sub>2</sub> had to be

\*Address correspondence to this author at the INSERM ERI25, “Muscle and Pathologies”, CHU A. de Villeneuve, 371 Avenue du Doyen Giraud, 34295 Montpellier, France; Tel: +33 467 335 910; Fax: +33 467 335 923; E-mail: ddelamplé@yahoo.fr

lower than 90% to be qualified for acute O<sub>2</sub> supply, i.e. ambulatory oxygen therapy. All patients were stable at the time of the study and no one was treated by long-term oxygen therapy or suffered from clinical cardiovascular, neurological, or any other disease that might have contributed to dyspnoea or exercise limitation. The protocol was explained to each subject and all gave written informed consent.

### Initial Assessments

All patients underwent pulmonary function testing including spirometry and lung volumes determined by plethysmography (V6200 Autobox; Sormedics; Yorba Linda, CA, USA). Measurements of resting arterial blood gas levels while the patients breathed room air were obtained during a period of clinical stability and quantified with a blood gas analyser (pHOx Plus L, Nova Biomedical, Waltham, MA, USA).

All patients performed a cardiopulmonary exercise test (CPET) on an electrically-braked cycle ergometer (Ergometrics 900; Ergoline; Bitz, Germany) following the individualized protocol usually used in our laboratory. On-line calculations of whole-body oxygen consumption (VO<sub>2</sub>) were averaged sequentially over 15-s intervals and displayed on a screen monitor to observe the progress of the test. Heart rate (HR) was measured continuously throughout the test by 12-lead electrocardiography. The ventilatory threshold was determined using the ventilatory equivalents of O<sub>2</sub> and CO<sub>2</sub> method [17].

### 6-Minute Walking Test (WT)

The WT was performed around a perimeter of 31.5 m. Each subject performed two tests to allow the observation of any variability due to "learning", with a rest of approximately 1 hour between tests. The second test was performed only if SpO<sub>2</sub> and HR were identical to the values before the first WT. Patients were asked to walk at their own maximal rate and we retained the greater distance of the two tests. They were asked to cover as much ground as possible in 6 minutes while maintaining a steady rate without running. No encouragement was given, and they were informed each minute of the remaining time. The patients were allowed to stop, but they could start again, if possible, within the allocated 6 minutes. Arterial oxygen saturation (SpO<sub>2</sub>) and HR were monitored throughout the walk every minute using a pulse oximeter (Nonin 8500 M; Nonin Medical, Inc., Minneapolis, MN, USA). The patients were asked to indicate their level of breathlessness using a visual analogue scale before and immediately after each walk.

### Determination of O<sub>2</sub> Flow

As there is no official consensus to individualize O<sub>2</sub> flow supply according to O<sub>2</sub> desaturation during the WT, we used the methodology of our clinic. This methodology has been used for several years and provides good re-saturation with SpO<sub>2</sub> equal to or above 90%. When the patient exhibits SpO<sub>2</sub> between 90 and 85%, an O<sub>2</sub> flow of 2 litres is given. When 84 ≥ SpO<sub>2</sub> ≥ 80%, O<sub>2</sub> flow amounts to 4 litres. For SpO<sub>2</sub> < 80%, O<sub>2</sub> flow is 5 litres. O<sub>2</sub> flow was *via* cylinder and nasal spears.

### Training Program (TP)

All patients participated in an in-patient training program for 4 weeks. The whole-body exercise training included sta-

tionary cycling, walking, swimming, and team sports. The exercise intensity was individualized according to target heart rate, i.e. the heart rate at the ventilatory threshold (VT) determined during CPET. This intensity was continuously monitored with a cardiofrequency meter and maintained throughout all exercise. The desaturator COPD patients did not always exhibit O<sub>2</sub> desaturation during TP and ambulatory O<sub>2</sub> was only used when necessary. For most of the program, in fact, they did not receive O<sub>2</sub>. Training sessions were held 6 days per week and lasted 45 minutes on average. Training volume per week was 15.1 ± 1.2 h on average and divided in four sessions of stationary cycling (45 minutes per session), three sessions of swimming and team sports (45 minutes per session) and 4 sessions of walking (one or two hours per session). All sessions were supervised by a physiotherapist.

### Protocol

Initial assessments were made on admission to the clinic. One to three days after CPET, all patients performed 2 WTs on the same day. The first test (basal WT [BWT]) was performed while they breathed room air. The second test (AIR-WT) was performed while they breathed compressed air. At least one day later the patients were tested during WT whilst breathing oxygen (O<sub>2</sub>-WT). The O<sub>2</sub>-WT was performed twice as it is well known that the best performance is generally obtained from the second test. Oxygen flow was adjusted in all patients to reach an SpO<sub>2</sub> > 90%. Before each WT, they breathed the gas mixture for 15 minutes. Two indistinguishable cylinders located at the middle of the walking perimeter, one with compressed air and one with O<sub>2</sub>, were connected to a 15-m tube ending in a nasal cannula. The patients did not know which gas was added. This experimental protocol was conducted by the same investigator before and after TP with the same flow of O<sub>2</sub> and compressed air.

### Statistical Analysis

Results are expressed as mean ± SEM. For each variable of interest, a two-way analysis of variance (ANOVA) with repeated measures was performed. One way was assigned for training condition (before/after) and the other for O<sub>2</sub> supply (without/with). When ANOVA detected a significant main effect, post-hoc comparisons were made using a Tukey test. The comparison between the oxygen responder group and the non-responder group was performed using an *unpaired t test*. Significant differences were declared when p < 0.05.

## RESULTS

### Baseline Characteristics

Table 1 shows the baseline characteristics of all the patients. The patients present a marked limitation of their aerobic capacity (VO<sub>2</sub>max = 50.4 ± 3.4% predicted). They had moderate chronic obstruction (FEV<sub>1</sub> = 52.1 ± 3% predicted) and mild resting hypoxemia (PaO<sub>2</sub> = 67.4 ± 1.5 mmHg). All patients showed clinical desaturation with a mean fall in SpO<sub>2</sub> equal to 12.1 ± 1.3% and SpO<sub>2</sub> at the end of WT equal to 81.1 ± 1.5%. During the O<sub>2</sub>-WT, 6 patients required a flow of 2 L, 8 patients required 4 L, and 8 patients required 5 L. O<sub>2</sub> administration thus prevented critical desaturation in all subjects and no patient had their SpO<sub>2</sub> level fall to < 90% (End O<sub>2</sub>-WT SaO<sub>2</sub> = 90.9 ± 0.6%).

**Table 1. Anthropometric, Spirometric and Physiological Data of COPD Patients Before Training Program**

Variables	Values
Age (yr)	61.9 ± 1.9
Female: Male	07: 15
BMI (kg/m <sup>2</sup> )	26.1 ± 0.9
Peak VO <sub>2</sub> (%predicted)	50.4 ± 3.4
Maximal HR (bpm)	125 ± 7
HR at ventilatory threshold (bpm)	115 ± 6
FEV <sub>1</sub> (% predicted)	52.1 ± 3
FEV <sub>1</sub> /FVC (%)	55.7 ± 2.7
PaO <sub>2</sub> (mmHg)	67.4 ± 1.5
AIR-WT distance (m)	458.2 ± 20
Baseline dyspnoea	1.3 ± 0.3
End AIR-WT dyspnoea	6.1 ± 0.6

Definition of abbreviations: BMI = body mass index; FVC: forced vital capacity; HR: heart rate. Values are mean ± SEM.

### O<sub>2</sub> Responses Before TP

Comparison of the distance walked during AIR-WT versus O<sub>2</sub>-WT showed a statistically significant effect of O<sub>2</sub> on walking distance (Table 2,  $p < 0.05$ ) with no change in HR at the end of WT. This increase in walking distance was associated with a significant effect of O<sub>2</sub> on dyspnoea ( $p < 0.05$ ), which was 6% lower at the end of O<sub>2</sub>-WT than at the end of AIR-WT. No effect of O<sub>2</sub> on HR at rest or at the end of WT was observed (Table 2). Nevertheless, high variability was noted in the O<sub>2</sub> response. In line with the literature, we con-


sidered the patients who increased their walking distance by at least 10% while breathing oxygen to be oxygen responders (see *Methodological considerations* in the discussion). Thus, compared with AIR-WT, during O<sub>2</sub>-WT 14 patients showed no improvement in exercise tolerance and 8 patients increased their walking distance ( $18.2 \pm 2.7\%$ , i.e.  $74 \pm 10.8$  m on average) (Fig. 1). No basal parameter predicted the occurrence of O<sub>2</sub> benefits during O<sub>2</sub>-WT. However, oxygen responders seemed to have greater disease severity than non-responders (FEV<sub>1</sub> =  $46.8 \pm 4.9\%$  predicted vs  $53.7 \pm 3.5\%$  predicted, respectively) as well as lower exercise tolerance (distance walked during AIR-WT before TP:  $407.5 \pm 27.5$  m vs  $487.2 \pm 24.6\%$  predicted, respectively;  $p < 0.05$ ).

### Effects of TP

Endurance capacity, measured as an increase in the distance walked during WT, improved significantly after 4 weeks of training ( $458.2 \pm 20$  m vs  $512.4 \pm 20.3$  m;  $p < 0.05$ ) for the entire population. The mean gain was 13.2% after training, or  $54.5 \pm 12.9$  m. Dyspnoea at rest and at the end of WT was significantly decreased after TP ( $p < 0.05$ ). TP had no significant effect on HR at rest or at the end of WT (Table 2). The benefits of TP on exercise tolerance were the same in oxygen responders and non-responders (distance walked by oxygen responders increased by  $67.4 \pm 29.5$  m and by non-responders,  $46.6 \pm 12.2$  m).

### O<sub>2</sub> Responses After TP

After TP, the same O<sub>2</sub> flow allocated before TP was used. On average, O<sub>2</sub> inhalation during WT increased the distance walked statistically but not clinically, compared with AIR-WT ( $512.4 \pm 20.3$  m vs  $538 \pm 19.9$  m, respectively;  $p < 0.05$ ). O<sub>2</sub> significantly decreased dyspnoea at the end of O<sub>2</sub>-WT ( $-9.3\%$  between dyspnoea at the end of AIR-WT and dyspnoea at the end of O<sub>2</sub>-WT;  $p < 0.05$ ). Despite the greater dis-



**Fig. (1).** Individual data on walk distance on six minute walk test (WT) after breathing compressed air or oxygen.

**Table 2. Effects of Acute Oxygen Supplementation and Training Program (TP) on WT in COPD Patients**

Variables	Before TP		After TP	
	AIR	O <sub>2</sub>	AIR	O <sub>2</sub>
Distance (m)	458.2 ± 20	489.6 ± 19.6†	512.4 ± 20.3*	537.9 ± 19.9*†
SpO <sub>2</sub> at rest (%)	93.2 ± 0.6	96.9 ± 0.4†	95 ± 0.8	97.1 ± 0.5†
SpO <sub>2</sub> at the end of the test (%)	81.1 ± 1.5	90.9 ± 0.7†	81.1 ± 1.4	91.3 ± 1†
Dyspnoea at rest	1.3 ± 0.3	0.9 ± 0.3	0.7 ± 0.3*	0.8 ± 0.3*
Dyspnoea at the end of the test	6.1 ± 0.6	5.5 ± 0.6†	5.6 ± 0.7*	4.7 ± 0.6*†
HR at rest (bpm)	92 ± 2.8	90.4 ± 2.5	89.8 ± 2.7	90.6 ± 2.8
HR at the end of the test (bpm)	117.7 ± 3	115.1 ± 3.4	119.3 ± 2.7	117 ± 3.4

Values are represented as mean ± SD.

\*: p<0.05 within group comparison before versus after rehabilitation.

†: p<0.05 comparison between O<sub>2</sub>-WT and the corresponding AIR-WT.

tances covered, HR was not modified by acute oxygen supply, before or after WT.

Individual responses to O<sub>2</sub> supply varied greatly. After TP, when patients breathed O<sub>2</sub> during WT, 6 increased their walking distance by > 10% (18.7%, i.e. 73.1 m on average) but 16 showed no improvement. When we compared data before and after TP, only 4 patients who were able to increase their walking distance with O<sub>2</sub> before TP had also improved their walking distance after TP. Thus, 4 patients who were oxygen responders before TP became non-responders after TP. And 2 patients who were oxygen non-responders before TP became responders after TP. Again, no baseline characteristic allowed us to predict either situation.

### Effect of Compressed Air on Walking Distance

Compressed air administration did not modify the results of the basal test in any patient. Walking distance during BWT was 415.4 ± 27 m and 419.5 ± 24.3 m, which corresponds to a 1.5% difference.

## DISCUSSION

The main result of this study reported that, despite the clinical benefits of TP, a prior TP did not optimize the acute effect of O<sub>2</sub> supply on desaturator COPD patients during a walking test. We also confirmed that the responses to O<sub>2</sub> supply of COPD patients show wide disparity during exercise.

### Methodological Considerations

*Choice of exercise.* The 6-minute walking test has been validated for the detection of therapeutic improvements in exercise tolerance and dyspnoea. It thus has been widely used to show that O<sub>2</sub> supply during exercise can improve tolerance [4, 5, 18]. Walking was reported to be associated with the lowest mean SpO<sub>2</sub> value when saturation was measured during several daytime activities [19]. In addition, WT is more sensitive to desaturation than other tests like cardiopulmonary exercise testing on cycle ergometer [1], and it provokes breathlessness. It thus appears to be a functional test well adapted to evaluating patients in their own daily surroundings.

*Protocol for O<sub>2</sub> supply.* Contrary to other studies which gave a pre-determined FIO<sub>2</sub> to their patients during exercise, we individualized the O<sub>2</sub> flow on the basis of the desaturation observed at the end of AIR-WT. This ensured that each patient reached a SpO<sub>2</sub> ≥ 90%. The O<sub>2</sub> supply protocol described above is regularly used in our institution and personal observation confirms that this individualized protocol effectively prevents desaturation during exertion. In our study, all our patients kept their SpO<sub>2</sub> ≥ 90% during WT (SpO<sub>2</sub> = 90.9 ± 0.7% at the end O<sub>2</sub>-WT).

*Oxygen response.* Studies on O<sub>2</sub> supply and its benefits always present their results as averages. A few recent studies have focused on the heterogeneity of these results. However, none have determined the threshold above which the increase in walking distance thanks to O<sub>2</sub> supply is clinically significant. In the literature, the variability between two WTs is less than 10% in many chronic diseases [20-24]. Moreover, Eiser *et al.* [25] observed an 8% variability between the WTs of COPD patients. We thus assumed that a variation above 10% should not be considered as variability but as clinically significant modification.

## Results Discussion

Our study demonstrated that before TP O<sub>2</sub> inhalation significantly increased the exercise tolerance of desaturator COPD patients. Several studies [5, 8, 26] have described improvements in the dyspnoea index and exercise performance when O<sub>2</sub> was administered only during exercise. Some [8, 26] also noted difficulties in predicting the response to O<sub>2</sub>. In our study, no basal or WT parameter (especially exercise-induced desaturation) reliably predicted the response to O<sub>2</sub> supply during exercise. Nevertheless, disease severity and exercise capacity before TP tended to be lower in the oxygen responders. On average, our patients presented moderate chronic airway limitation (FEV<sub>1</sub> = 52.1 ± 3% predicted) and Fujimoto *et al.* showed that patients with moderate severity (FEV<sub>1</sub> > 50% predicted) did not improve exercise capacity to the same extent as did patients with more severe disease, indicating that O<sub>2</sub> supply during exercise might be useful only in patients with moderate to severe disease. Somfay *et al.* [9] demonstrated that O<sub>2</sub> supply during exercise induced dose-dependent improvement in endurance and symptom perception in COPD patients. In our study, we used a low O<sub>2</sub> flow, which was nevertheless individualized. It is

possible that in these conditions, the response to O<sub>2</sub> during exercise is less remarkable and not so clinically significant. But in our case, we observed the real effects of acute O<sub>2</sub> supplementation as it is prescribed in medical institutions.

Most studies have reported a wide range of individual responses to O<sub>2</sub>, as did ours. It must be emphasized that the effects of hyperoxia are multifactorial and involve many integrated mechanisms. During O<sub>2</sub> breathing in this study, the end O<sub>2</sub>-WT heart rate was similar to air-WT despite the greater distances covered by the patients. In addition, acute O<sub>2</sub> supply significantly reduced perceived dyspnoea at the end of WT. Jolly *et al.* [7] suggested that cardiovascular limitation could be implicated in the response to O<sub>2</sub> during exercise. Moreover, in addition to the diffusion limitation in the lung, a diffusion limitation at the level of the skeletal muscles may be present [27]. Supplemental O<sub>2</sub> may thus fail to enhance muscle O<sub>2</sub> utilization during exercise in COPD patients with peripheral muscle weakness [28]. One hypothesis to explain our heterogeneous responses is thus that in hyperoxic conditions, the above-mentioned mechanisms are involved but to different degrees in each patient.

On average, the response to O<sub>2</sub> supply during exercise was not modified by TP. Although we observed an effect of O<sub>2</sub> after TP on walking distance and dyspnoea, the combination of prior TP and acute O<sub>2</sub> supply during exercise had no cumulative effect on the exercise tolerance of COPD patients who present exercise-induced desaturation. TP was, however, efficient in increasing exercise tolerance. Indeed, after training, the distance walked during WT was statistically and clinically increased and dyspnoea was significantly decreased with a heart rate at the end of the WT similar to that before TP. These results confirm the beneficial effects of individualized training on exercise tolerance in COPD patients. Exercise training induces cardiovascular benefits (with a gain in spontaneous baroreflex sensitivity) [29] and pulmonary benefits. Casaburi *et al.* [12] demonstrated more efficient exercise breathing patterns and lower ventilation (with increase in tidal volume). TP also produces changes in skeletal muscles (increased oxidative metabolism activity and mean fibre area) [13, 30]. In summary, TP improves exercise tolerance by inducing central (cardiopulmonary) and peripheral (peripheral skeletal muscle) adaptations. The success of O<sub>2</sub> supply is also likely to depend on its net effects on cardiopulmonary and peripheral muscle functions [31]. As no cumulative effect of TP plus acute O<sub>2</sub> supplementation was seen, we can hypothesize that the training modalities of our TP led to central adaptations but could not be adjusted enough to induce peripheral adaptations. More resistance training in this TP would probably induce peripheral adaptations more efficiently since little demand is placed on the cardiopulmonary system [32] during this type of exercise, making it well tolerated by COPD patients. But possibly we did not observe a greater response to O<sub>2</sub> after TP because the effects of TP far exceeded the acute effects of O<sub>2</sub>. Many factors account for the absence of a cumulative effect of training and O<sub>2</sub> supply during exercise. The contribution of exercise-induced desaturation to exercise limitation is still uncertain, and the mechanisms by which O<sub>2</sub> affects exercise tolerance are complex. The present study confirmed previous reports that showed that the acute effects of O<sub>2</sub>, as well as the effects of training, do not correlate with lung function parameters or blood gas values at rest or during exercise [4, 33,

34]. Furthermore, in the present study, the acute effects of O<sub>2</sub> did not predict the effects of training in individual subjects. Hence, patients with a poor response to O<sub>2</sub> are not necessarily poor candidates for training. These findings suggest that oxygen and training may influence exercise tolerance by different mechanisms.

In summary, this study confirmed the great heterogeneity in responses to O<sub>2</sub> supply during exercise, with approximately 35% of our COPD patients improving their exercise tolerance. The training program did not modify this response to O<sub>2</sub>, suggesting that efficient O<sub>2</sub> utilization does not depend on muscular and central benefits of TP. Moreover, basal parameters and exercise-desaturation do not seem to be reliable criteria for selecting those patients who will most benefit from O<sub>2</sub> during activities. As the response to this therapy is unpredictable, every patient should be individually evaluated.

## REFERENCES

- [1] Poulain M, Durand F, Palomba B, *et al.* 6-minute walk testing is more sensitive than maximal incremental cycle testing for detecting oxygen desaturation in patients with COPD. *Chest* 2003; 123(5): 1401-7.
- [2] Turner SE, Eastwood PR, Cecins NM, Hillman DR, Jenkins SC. Physiologic responses to incremental and self-paced exercise in COPD: a comparison of three tests. *Chest* 2004; 126(3): 766-73.
- [3] Bradley JM, Lasserson T, Elborn S, Macmahon J, O'Neill B. A systematic review of randomized controlled trials examining the short-term benefit of ambulatory oxygen in COPD. *Chest* 2007; 131(1): 278-85.
- [4] Davidson AC, Leach R, George RJ, Geddes DM. Supplemental oxygen and exercise ability in chronic obstructive airways disease. *Thorax* 1988; 43(12): 965-71.
- [5] Dean NC, Brown JK, Himelman RB, Doherty JJ, Gold WM, Stulbarg MS. Oxygen may improve dyspnea and endurance in patients with chronic obstructive pulmonary disease and only mild hypoxemia. *Am Rev Respir Dis* 1992; 146(4): 941-5.
- [6] O'Donnell DE, D'Arsigny C, Webb KA. Effects of hyperoxia on ventilatory limitation during exercise in advanced chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2001; 163(4): 892-8.
- [7] Jolly EC, Di Boscio V, Aguirre L, Luna CM, Berensztein S, Gene RJ. Effects of supplemental oxygen during activity in patients with advanced COPD without severe resting hypoxemia. *Chest* 2001; 120(2): 437-43.
- [8] Fujimoto K, Matsuzawa Y, Yamaguchi S, Koizumi T, Kubo K. Benefits of oxygen on exercise performance and pulmonary hemodynamics in patients with COPD with mild hypoxemia. *Chest* 2002; 122(2): 457-63.
- [9] Somfay A, Porszasz J, Lee SM, Casaburi R. Dose-response effect of oxygen on hyperinflation and exercise endurance in nonhypoxaemic COPD patients. *Eur Respir J* 2001; 18(1): 77-84.
- [10] Dewan NA, Bell CW. Effect of low flow and high flow oxygen delivery on exercise tolerance and sensation of dyspnea. A study comparing the transtracheal catheter and nasal prongs. *Chest* 1994; 105(4): 1061-5.
- [11] Longo AM, Moser KM, Luchsinger PC. The role of oxygen therapy in the rehabilitation of patients with chronic obstructive pulmonary disease. *Am Rev Respir Dis* 1971; 103(5): 690-7.
- [12] Casaburi R, Porszasz J, Burns MR, Carithers ER, Chang RS, Cooper CB. Physiologic benefits of exercise training in rehabilitation of patients with severe chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 1997; 155(5): 1541-51.
- [13] Maltais F, LeBlanc P, Simard C, *et al.* Skeletal muscle adaptation to endurance training in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 1996; 154(2 Pt 1): 442-7.
- [14] Vallet G, Ahmadi S, Serres I, *et al.* Comparison of two training programmes in chronic airway limitation patients: standardized versus individualized protocols. *Eur Respir J* 1997; 10(1): 114-22.
- [15] Casaburi R, Patessio A, Ioli F, Zanaboni S, Donner CF, Wasserman K. Reductions in exercise lactic acidosis and ventilation as a result

- of exercise training in patients with obstructive lung disease. *Am Rev Respir Dis* 1991; 143(1): 9-18.
- [16] Rabe KF, Hurd S, Anzueto A, *et al.* Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: GOLD Executive Summary. *Am J Respir Crit Care Med* 2007; 176(6): 532-55.
- [17] Wasserman K. The anaerobic threshold: definition, physiological significance and identification. *Adv Cardiol* 1986; 35: 1-23.
- [18] Leach RM, Davidson AC, Chinn S, Twort CH, Cameron IR, Bateman NT. Portable liquid oxygen and exercise ability in severe respiratory disability. *Thorax* 1992; 47(10): 781-9.
- [19] Soguel Schenkel N, Burdet L, de Muralt B, Fitting JW. Oxygen saturation during daily activities in chronic obstructive pulmonary disease. *Eur Respir J* 1996; 9(12): 2584-9.
- [20] Andersson C, Asztalos L, Mattsson E. Six-minute walk test in adults with cerebral palsy. A study of reliability. *Clin Rehabil* 2006; 20(6): 488-95.
- [21] Kervio G, Ville NS, Leclercq C, Daubert JC, Carre F. Cardiorespiratory adaptations during the six-minute walk test in chronic heart failure patients. *Eur J Cardiovasc Prev Rehabil* 2004; 11(2): 171-7.
- [22] Montgomery PS, Gardner AW. The clinical utility of a six-minute walk test in peripheral arterial occlusive disease patients. *J Am Geriatr Soc* 1998; 46(6): 706-11.
- [23] Opasich C, Pinna GD, Mazza A, *et al.* Reproducibility of the six-minute walking test in patients with chronic congestive heart failure: practical implications. *Am J Cardiol* 1998; 81(12): 1497-500.
- [24] Roomi J, Johnson MM, Waters K, Yohannes A, Helm A, Connolly MJ. Respiratory rehabilitation, exercise capacity and quality of life in chronic airways disease in old age. *Age Ageing* 1996; 25(1): 12-6.
- [25] Eiser N, Willsher D, Dore CJ. Reliability, repeatability and sensitivity to change of externally and self-paced walking tests in COPD patients. *Respir Med* 2003; 97(4): 407-14.
- [26] Woodcock AA, Gross ER, Geddes DM (1981). Oxygen relieves breathlessness in "pink puffers". *Lancet* 1981; 25; 1(8226): 907-9.
- [27] Wagner PD. Algebraic analysis of the determinants of VO<sub>2</sub>, max. *Respir Physiol* 1993; 93(2): 221-37.
- [28] Gosselink R, Decramer M. Peripheral skeletal muscles and exercise performance in patients with chronic obstructive pulmonary disease. *Monaldi Arch Chest Dis* 1998; 53(4): 419-23.
- [29] Costes F, Roche F, Pichot V, Vergnon JM, Garet M, Barthelemy JC. Influence of exercise training on cardiac baroreflex sensitivity in patients with COPD. *Eur Respir J* 2004; 23(3): 396-401.
- [30] Montes de Oca M, Torres SH, Gonzalez Y, Romero E, Hernandez N, Talamo C. [Changes in exercise tolerance, health related quality of life, and peripheral muscle characteristics of chronic obstructive pulmonary disease patients after 6 weeks' training]. *Arch Broncopneumol* 2005; 41(8): 413-8.
- [31] O'Donnell DE, Bain DJ, Webb KA. Factors contributing to relief of exertional breathlessness during hyperoxia in chronic airflow limitation. *Am J Respir Crit Care Med* 1997; 155(2): 530-5.
- [32] Richardson RS, Sheldon J, Poole DC, Hopkins SR, Ries AL, Wagner PD. Evidence of skeletal muscle metabolic reserve during whole body exercise in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 1999; 159(3): 881-5.
- [33] Light RW, Mahutte CK, Stansbury DW, Fischer CE, Brown SE. Relationship between improvement in exercise performance with supplemental oxygen and hypoxic ventilatory drive in patients with chronic airflow obstruction. *Chest* 1989; 95(4): 751-6.
- [34] Rooyackers JM, Dekhuijzen PN, Van Herwaarden CL, Folgering HT. Training with supplemental oxygen in patients with COPD and hypoxaemia at peak exercise. *Eur Respir J* 1997; 10(6): 1278-84.